Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks
- 作者：Hongming Huang ; Yan Qin ; Ruirong Xu ; Xuefeng You ; Rong Teng ; Li Yang ; Mengqi Xu ; Hong Liu ; hongliu63@126.com
- 关键词：Acute promyelocytic leukemia ; Arsenic trioxide ; All-trans retinoic acid ; Chemotherapy
- 刊名：Leukemia Research
- 出版年：2012
- 期刊代码：186_01452126
- 类别：med
- 出版时间：July, 2012
- 卷：36
- 期：7
- 页码：841-845
- 文件大小：348 K
摘要
To improve the recovery rate of high-risk patients with acute promyelocytic leukemia (APL), we used all-trans retinoic acid (ATRA)/arsenic trioxide (ATO)/daunorubicin combination in remission induction, daunorubicin and cytarabine in consolidation, and ATRA/ATO/methotrexate 卤 6-mercaptopurine in maintenance treatment of APL patients with various risks for relapse. Our results showed a high complete remission rate of 95.3%. Excluding the cases of early-death, no significant differences in event-free survival were observed between the intermediate-risk and high-risk group (p = 0.393) and the low-risk and high-risk group (p = 0.162). In addition, there were no significant differences between the groups in cumulative incidence of central nervous system relapse. In conclusion, our results suggest that APL patients benefit from combination ATO/ATRA/chemotherapy, and that this regimen is especially beneficial for patients with high-risk prognostic factors.